Investing.com - Financial Markets Worldwide
🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Mizuho Securities Stick to Their Buy Rating for Arcus Biosciences Inc

Published 07/19/2021, 07:35 PM
RCUS
-


Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences (NYSE:RCUS) Inc on Monday, setting a price target of $43, which is approximately 45.91% above the present share price of $29.47.

Goldstein expects Arcus Biosciences Inc to post earnings per share (EPS) of -$1.08 for the third quarter of 2021.

The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Arcus Biosciences, with an average price target of $52.
The analysts price targets range from a high of $60 to a low of $43.

In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $9.46 million and a net profit of -$72.75 million. The company's market cap is $2.09 billion.

According to TipRanks.com, Mizuho Securities analyst Mara Goldstein is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.6% and a 37.92% success rate.

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.